Journal of Clinical Oncology
Articles in this Issue
Effect of ROCK2 signaling on resistance to KRAS inhibitors in pancreatic cancer.
756 Background: Inhibitors targeting mutant and wildtype forms of KRAS, which is a key driver of pancreatic oncogenesis in...
Use of circulating tumor DNA (ctDNA) to monitor patients undergoing total neoadjuvant treatment (TNT) for locally advanced rectal adenocarcinoma (LARC).
30 Background: While many patients with LARC experience durable responses after TNT, relapse risk remains a concern and is...
Early vs late onset primary colon adenocarcinoma: Gene expression dependent overall survival in chemotherapy treated TCGA-COAD patients.
233 Background: Early-onset (EO, <50y) and late-onset (LO, ≥50y) colorectal cancers differ biologically and prognostica...
Efficacy and safety of ponsegromab in patients with colorectal cancer and cachexia: A subgroup analysis of the PROACC-1 phase 2 study.
110 Background: Ponsegromab is a monoclonal antibody that inhibits growth differentiation factor 15 (GDF-15), a circulatin...
Inferring optimal detection of <i>MTAP</i> homozygous loss (homozygous deletion) in pancreatic cancer: Association with treatment exposure, co-alterations, site of biopsy, and clinical outcomes.
684 Background: Validated homozygous loss detection is becoming increasingly important in clinical practice, with...
Postoperative complications and overall survival in elderly patients with gastric cancer: A retrospective study.
336 Background: Japan is one of the fastest-aging countries in the world, and the number of elderly patients undergoing su...
The time toxicity of metastatic pancreatic cancer treatment.
673 Background: Optimal care for pancreatic adenocarcinoma (PDAC) involves multimodal treatment from numerous providers, w...
Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): 4-year follow-up of CheckMate 9DW.
LBA479 Background: At a preplanned interim analysis of CheckMate 9DW (NCT04039607), with 35.2 months of median follow-up,...
A phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227 (GSK’227), alone and in combination in patients with previously treated advanced unresectable or metastatic gastrointestinal solid tumors.
TPS264 Background: B7-homolog 3 protein (B7-H3), an immune checkpoint protein, is overexpressed in many types of solid tum...
A phase 1 trial of the oncolytic virus SVV-001 in combination with nivolumab and ipilimumab in patients with poorly differentiated neuroendocrine carcinomas or well-differentiated grade 3 neuroendocrine tumors.
TPS650 Background: High-grade neuroendocrine neoplasms (NENs), including poorly differentiated neuroendocrine carcinomas (...
<i>DPYD</i> testing in GI cancers: A real-world analysis of costs and quality of care.
821 Background: Fluoropyrimidines are foundational agents in GI oncology, however they can cause severe toxicity in patien...
Reducing the resection range after neoadjuvant therapy for locally advanced upper rectal and rectosigmoid junction cancers (RESET): A prospective, multicenter, randomized controlled phase 3 study.
TPS271 Background: Locally advanced colorectal cancer (LACRC) is recommended to receive neoadjuvant chemotherapy(NCT) by t...
5hmC as a novel liquid biopsy biomarker for colorectal cancer to enable detection and unveil tumor biology.
228 Background: 5-hydroxymethylcytosine (5hmC) is a DNA epigenetic modification which regulates gene expression and is ass...
Safety and preliminary efficacy results of [ <sup>212</sup> Pb]VMT-a-NET in advanced somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors (NETs).
635 Background: [ 212 Pb]VMT-a-NET is an alpha therapy agent targeting somatostati...
Neoadjuvant epacadostat (INCB024360) combined with short course radiotherapy in patients with locally advanced rectal cancer: Efficacy and safety from a phase 2 trial.
162 Background: In preclinical studies, the tryptophan-metabolizing enzyme, Indoleamine 2, 3-dioxygenase 1 (IDO1), promote...
Apixaban versus rivaroxaban for venous thromboembolism in gastric cancer: Insights from a propensity-matched cohort study.
420 Background: Patients with gastric cancer complicated by venous thromboembolism (VTE) often require anticoagulation. Th...
Surgical journey for participants (pts) in the MATTERHORN trial: A global, randomized, phase 3 study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma.
353 Background: In MATTERHORN (NCT04592913), perioperative D + FLOT significantly improved event-free survival (EFS) vs pl...
Phase II trial of early-line anti-EGFR therapy to facilitate retreatment for select patients with metastatic colorectal cancer.
165 Background: Metastatic colorectal cancer (mCRC) is subdivided based on sidedness and molecular characteristics to guid...
Correlation between the timing of recurrence and circulating tumor DNA (ctDNA) doubling time in patients (pts) with resected colon cancer.
220 Background: Previous studies have demonstrated that persistent ctDNA positivity in pts with colon cancer is associated...
Efficacy and safety of retifanlimab in gastrointestinal malignancies: A systematic review of clinical trials.
841 Background: Retifanlimab is a humanized anti–PD-1 monoclonal antibody, recently approved in May 2025, for advanced squ...
Predictive value of CLDN18.2 <sup>+</sup> CD8 <sup>+</sup> T cells in peripheral blood and tumor tissue for immunotherapy response and survival in gastric and pancreatic cancers.
750 Background: CLDN18.2 has emerged as a therapeutic target in gastric cancer (GC) and pancreatic ductal adenocarcinoma (...
Artificial intelligence-assisted endoscopic diagnosis of upper gastrointestinal neoplasia: A systematic review and meta-analysis of randomized controlled trials and diagnostic test accuracy studies.
338 Background: Upper gastrointestinal (GI) cancers represent a major global health burden, often diagnosed at advanced st...
5-FU freedom: Patient perspectives from COLONTOWN on the practice of pump self-disconnect.
102 Background: Patients with colorectal cancer (CRC) and their caregivers often describe the extra clinic visit to discon...
Clinical outcomes of resected gastrointestinal stromal tumors treated with 3 years of adjuvant imatinib in different genotypes.
839 Background: Surgical resection followed by 3 years of adjuvant imatinib is standard for high-risk resectable gastroint...
Trends in gastric cancer mortality by subsite (cardia vs. non-cardia) and racial disparities from 1999-2023.
298 Background: Gastric cancer is uncommon in the U.S. but has a poor prognosis. We compared mortality trends for cardia v...